According to the American College of Medical Genetics and Genomics (ACMG) guidelines, any patient with a known pathogenic or likely pathogenic variant in BRCA1/2 in any tumor type should be further investigated with germline testing to look for germline mutations (Kalia et al. 2017). The gene discussed is BRCA1; the disease is neoplasm.